In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on ACADIA Pharmaceuticals (ACAD), with a price target of $66.00. The company’s shares closed last Monday at $44.28, close to its 52-week high of $48.27.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 25.0% and a 52.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on ACADIA Pharmaceuticals is a Strong Buy with an average price target of $55.58, a 23.3% upside from current levels. In a report issued on November 26, Needham also maintained a Buy rating on the stock with a $60.00 price target.
See today’s analyst top recommended stocks >>
Based on ACADIA Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $41.98 million. In comparison, last year the company had a GAAP net loss of $62.14 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment.
